Skip to content

A Message To Our Clients

A Message To Our Clients

To Our Clients,


First of all, I hope everyone is staying safe and healthy in these unprecedented times.  I want to assure you that Arfinn Med has systems in place to ensure that our workflows are not impacted from having staff work remotely and we will continue to provide the same quality product and customer service that you have become accustomed to.  If you have any questions regarding our Business Continuation Plan, please reach out to info@arfinnmed.com.


We understand that routines will be temporarily changed in the coming months, so we are adapting to accommodate this change.  This means building out a more robust telemedicine system, increasing our patient portal functionality,  generating consents to be e-signed, and streamlining our patient intake process to cut down on wait times.  


As we settle into new workflows and challenges, we will suspend all monthly fees for using Arfinn Med until June 1st.  We also will activate our full suite of functionality to all current users so you are able to offer the best care to patients in the interim.  We know this doesn’t seem like much in these times, but we want to show our gratitude to the medical professionals who are on the front lines helping patients get the help they desperately need.  If you haven’t already, you will be seeing these updates on your account over the weekend. 


Please stay safe, and let us know if you require anything to continue running your practices.  I have set aside a development team to continually assess how to improve care and keep stakeholders safe.
Sincerely, 


James West CEO

Stories you may be interested in

Survey of oncologists finds knowledge gap on medical marijuana

As more states legalize medical marijuana, two key groups — researchers whose job is it to understand its benefits and drawbacks, and physicians charged with advising potential users — are struggling to catch up with policymakers. Ilana Braun, an assistant professor of psychiatry at Harvard Medical School and chief of the division of adult psychosocial…
Read More →

Americans Are Googling CBD More Than Acupuncture, Meditation And Exercise, Study Finds

People are increasingly more interested in CBD—or cannabidiol—than other health trends such as acupuncture, apple cider vinegar, exercise and veganism, according to a new review. In fact, the non-intoxicating cannabis compound has risen in popularity so much that people Google it nearly as much as they do for yoga and e-cigarettes. In a paper published…
Read More →

Cannabis and Seniors

As more and more research comes out regarding the medical benefits of cannabis, it’s important to keep up with new research as it becomes available.  Here at Arfinn Med, we constantly review new studies and look at our own deidentified efficacy data to try to find any additional insights we can relay to our registered…
Read More →

New Feature: Calendar Integration

At Arfinn Med, we’re excited to announce the third feature update to join automated text messaging and note templating: calendar integration. With this addition, physicians can now integrate their Google Calendar or Calendy account. The implementation of calendar integration rounds out the Arfinn Med portal, making it a physician’s one-stop-shop EMR tool. How It Works…
Read More →

Alternative Mississippi medical marijuana program barely wins approval from Senate

JACKSON • Legislation that would create a new medical marijuana program in Mississippi if the voter-approved Initiative 65 is overturned in court cleared the state Senate on the second try last week early on Friday morning. Senate Bill 2765, the Mississippi Medical Cannabis Act, failed by a single vote Thursday evening. But six hours later, after…
Read More →

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city. MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and…
Read More →

Leave a Comment

You must be logged in to post a comment.